Retension Pharmaceuticals, Inc. (RTSN)
NASDAQ: RTSN · Real-Time Price · USD
15.50
+0.50 (3.33%)
At close: Oct 22, 2026, 4:00 PM EDT
16.38
+0.88 (5.68%)
After-hours: Oct 22, 2026, 7:50 PM EDT

Retension Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Selling, General & Admin
2.431.770.980.25
Research & Development
12.445.111.30.02
Operating Expenses
14.866.882.280.27
Operating Income
-14.86-6.88-2.28-0.27
Interest & Investment Income
0.620.580.360.06
Other Non Operating Income (Expenses)
--0.02-
Pretax Income
-14.24-6.3-1.91-0.21
Net Income
-14.24-6.3-1.91-0.21
Net Income to Common
-14.24-6.3-1.91-0.21
Net Income Growth
----
Shares Outstanding (Basic)
1111
Shares Outstanding (Diluted)
1111
Shares Change
----
EPS (Basic)
-17.67-7.83-2.37-0.26
EPS (Diluted)
-17.67-7.83-2.37-0.26
EPS Growth
----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
EBIT
-14.86-6.88-2.28-0.27
SEC Filings: 10-K · 10-Q